Reporting, investigating and recalling suspected defective medicinal products to the Defective Medicines Report Centre (DMRC).
Similar Posts
Clinical trials for medicines: labelling
Guidance on labelling for medicinal products used in clinical trials.
IXCHIQ Chikungunya vaccine: temporary suspension in people aged 65 years or older
The Commission on Human Medicines (CHM) has temporarily restricted use of the IXCHIQ Chikungunya vaccine in people aged 65 years and over following very rare fatal reactions reported globally. This is a precautionary measure while the MHRA conducts a safety review. The IXCHIQ vaccine will be available on the UK market from 18 June 2025.
Decision: Marketing authorisations granted in 2025
Marketing authorisations granted in 2025.
Cosmetic Breast Augmentation Risk Awareness Tool
New Cosmetic Breast Augmentation Risk Awareness Tool for patients to use when considering cosmetic breast implant surgery.
Decision: Suspended and revoked licences and registrations for manufacturers and wholesalers of medicines and ingredients
Public list of companies in the UK who have had their licence/registration to manufacture or wholesale medicines/ingredients revoked or suspended.
MHRA phase I accreditation scheme
How to join the phase I accreditation scheme.